Chelsea Therapeutics Investor Buyout Alert - Acquisition Of Chelsea Therapeutics - Leading National Securities Law Firm Seeks Higher Price For Shareholders

NEW YORK, May 8, 2014

The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Chelsea for not acting in Chelsea shareholders' best interests in connection with the sale process of Chelsea.  The investigation seeks to determine if there was an adequate auction process and if Lundbeck is underpaying for Chelsea shares.  Indeed, analysts have projected that the true going forward inherent value of the company is worth at least $12 per share.  Further, Chelsea stock traded as high as $6.83 per share just a few months ago.  Moreover, the companies stated that there can be assurance that any or all of the CVRs will be made to shareholders.

If you are a shareholder of Chelsea and would like additional information regarding this matter, at no cost or expense, please contact us at:

Tripp Levy PLLC
New York, New York
Toll free: 1-800-511-7037
Email: contact@tripplevy.com 
www.tripplevy.com

Tripp Levy PLLC represents individual and institutional investors in shareholder actions and, along with its affiliates, has recovered billions of dollars for shareholders in securities actions.  Tripp Levy PLLC has become affiliated with Milberg LLP.  Attorney advertising.  Prior results do not indicate a similar outcome 

SOURCE Tripp Levy PLLC